JP2008519847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519847A5 JP2008519847A5 JP2007541338A JP2007541338A JP2008519847A5 JP 2008519847 A5 JP2008519847 A5 JP 2008519847A5 JP 2007541338 A JP2007541338 A JP 2007541338A JP 2007541338 A JP2007541338 A JP 2007541338A JP 2008519847 A5 JP2008519847 A5 JP 2008519847A5
- Authority
- JP
- Japan
- Prior art keywords
- myoclonus
- pharmaceutical composition
- phenylacetoxy
- alkanoyloxy
- benzoyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002033 Myoclonus Diseases 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000004423 acyloxy group Chemical group 0.000 claims 8
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims 8
- -1 phenylacetoxy Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 208000014094 Dystonic disease Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 208000010118 dystonia Diseases 0.000 claims 3
- 208000000269 Hyperkinesis Diseases 0.000 claims 2
- VWYANPOOORUCFJ-UHFFFAOYSA-N alpha-Fernenol Chemical compound CC1(C)C(O)CCC2(C)C3=CCC4(C)C5CCC(C(C)C)C5(C)CCC4(C)C3CCC21 VWYANPOOORUCFJ-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000006517 essential tremor Diseases 0.000 claims 2
- 229960003928 sodium oxybate Drugs 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- XYGBKMMCQDZQOZ-UHFFFAOYSA-M sodium;4-hydroxybutanoate Chemical compound [Na+].OCCCC([O-])=O XYGBKMMCQDZQOZ-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62664504P | 2004-11-10 | 2004-11-10 | |
| PCT/US2005/040877 WO2006053186A2 (en) | 2004-11-10 | 2005-11-09 | Method for treatment of movement disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008519847A JP2008519847A (ja) | 2008-06-12 |
| JP2008519847A5 true JP2008519847A5 (https=) | 2009-01-08 |
Family
ID=36337239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007541338A Pending JP2008519847A (ja) | 2004-11-10 | 2005-11-09 | 運動障害の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090137565A1 (https=) |
| EP (1) | EP1809286A4 (https=) |
| JP (1) | JP2008519847A (https=) |
| KR (1) | KR20070085838A (https=) |
| CN (1) | CN101098701A (https=) |
| AU (1) | AU2005304352A1 (https=) |
| CA (1) | CA2586975A1 (https=) |
| IL (1) | IL182906A0 (https=) |
| MX (1) | MX2007005679A (https=) |
| WO (1) | WO2006053186A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8702629B2 (en) * | 2005-03-17 | 2014-04-22 | Great Lakes Neuro Technologies Inc. | Movement disorder recovery system and method for continuous monitoring |
| US12263009B1 (en) * | 2005-03-17 | 2025-04-01 | Great Lakes Neurotechnologies Inc. | Movement disorder continuous monitoring and therapy system |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| US8771735B2 (en) | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| CN101919811A (zh) * | 2009-06-09 | 2010-12-22 | 北京博时安泰液体制剂科技有限公司 | 一种左乙拉西坦注射液及其制备方法 |
| MX391660B (es) | 2010-03-24 | 2025-03-21 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| CN113061089A (zh) | 2015-09-23 | 2021-07-02 | 凯瑞康宁生物工程（武汉）有限公司 | γ-羟基丁酸的前药及其组合物和用途 |
| FR3049463B1 (fr) * | 2016-04-01 | 2019-07-05 | Debregeas Et Associes Pharma | Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique |
| US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US11986659B2 (en) | 2018-03-22 | 2024-05-21 | Research Foundation Of The City University Of New York | Modulation of neuronal NKCC1 as a therapeutic strategy for spasticity and related disorders |
| BR112021006027A2 (pt) | 2018-11-19 | 2021-06-29 | Jazz Pharmaceuticals Ireland Limited | formulações de fármaco resistente a álcool |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| EP4037550A4 (en) * | 2019-09-30 | 2023-11-08 | Massachusetts Eye and Ear Infirmary | OBJECTIVE ASSESSMENT OF NEUROLOGICAL MOVEMENT DISORDERS FROM MEDICAL IMAGING |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| US12208266B2 (en) | 2020-05-26 | 2025-01-28 | Research Foundation Of The City University Of New York | Multi-site neuromodulation for treatment of ALS and related disorders |
| US12582622B2 (en) | 2020-10-08 | 2026-03-24 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2024163966A1 (en) | 2023-02-03 | 2024-08-08 | Tris Pharma, Inc. | Low sodium oxybate once nightly composition |
| WO2026037224A1 (zh) * | 2024-08-14 | 2026-02-19 | 南京纽邦生物科技有限公司 | 提高或维持酮体水平、改善代谢功能的方法和组合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4051842A (en) * | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) * | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| US4383529A (en) * | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| JPS60168044A (ja) * | 1984-02-10 | 1985-08-31 | Sharp Corp | 感湿素子 |
| IL72684A (en) * | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4738985A (en) * | 1986-03-19 | 1988-04-19 | The University Of Toronto Innovations Foundations | Pharmaceutical composition and treatment |
| US5145682A (en) * | 1986-05-30 | 1992-09-08 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration |
| US5990162A (en) * | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
| DK1140061T3 (da) * | 1998-12-23 | 2003-08-25 | Orphan Medical Inc | Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi |
| ES2383673T3 (es) * | 2000-09-22 | 2012-06-25 | Jpi Commercial, Llc | Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos |
| US8193211B2 (en) * | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
-
2005
- 2005-11-09 MX MX2007005679A patent/MX2007005679A/es not_active Application Discontinuation
- 2005-11-09 CN CNA2005800424239A patent/CN101098701A/zh active Pending
- 2005-11-09 WO PCT/US2005/040877 patent/WO2006053186A2/en not_active Ceased
- 2005-11-09 KR KR1020077012803A patent/KR20070085838A/ko not_active Withdrawn
- 2005-11-09 AU AU2005304352A patent/AU2005304352A1/en not_active Abandoned
- 2005-11-09 CA CA002586975A patent/CA2586975A1/en not_active Abandoned
- 2005-11-09 US US11/667,530 patent/US20090137565A1/en not_active Abandoned
- 2005-11-09 EP EP05847768A patent/EP1809286A4/en not_active Withdrawn
- 2005-11-09 JP JP2007541338A patent/JP2008519847A/ja active Pending
-
2007
- 2007-05-01 IL IL182906A patent/IL182906A0/en unknown